Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
Real-time Euronext Paris  -  11:35 2022-06-29 am EDT
1.124 EUR   -0.53%
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/27Erytech's combined shareholders meeting on june 24, 2022
AQ
06/27Top Premarket Decliners
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
1.142(c) 1.142(c) 1.12(c) 1.13(c) 1.124(c) Last
33 501 14 066 60 827 15 252 6 656 Volume
+0.97% 0.00% -1.93% +0.89% -0.53% Change
More quotes
Estimated financial data (e)
Sales 2022 9,20 M 9,63 M 9,63 M
Net income 2022 -52,8 M -55,3 M -55,3 M
Net Debt 2022 1,50 M 1,57 M 1,57 M
P/E ratio 2022 -0,50x
Yield 2022 -
Sales 2023 31,6 M 33,1 M 33,1 M
Net income 2023 -41,0 M -42,9 M -42,9 M
Net Debt 2023 38,0 M 39,8 M 39,8 M
P/E ratio 2023 -0,97x
Yield 2023 -
Capitalization 34,9 M 36,5 M 36,5 M
EV / Sales 2022 3,95x
EV / Sales 2023 2,31x
Nbr of Employees 181
Free-Float 98,5%
More Financials
Company
ERYTECH Pharma S.A. is a biopharmaceutical company in the clinical stage that develops innovative therapies based on red blood cells to fight cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, a new technology for encapsulating drugs in red blood cells, ERYTECH Pharma S.A. is developing a portfolio of product candidates targeting markets with significant unmet medical needs. eryaspase, the... 
Read more
More about the company
Ratings of ERYTECH Pharma S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ERYTECH PHARMA S.A.
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/27Erytech's combined shareholders meeting on june 24, 2022
AQ
06/27Top Premarket Decliners
MT
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
GL
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
AQ
06/23European ADRs Move Lower in Thursday Trading
MT
06/17European ADRs Move Lower in Friday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14European ADRs Move Lower in Tuesday Trading
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/07European ADRs Move Higher in Tuesday Trading
MT
06/02European ADRs Nudge Lower in Thursday Trading
MT
06/02Top Premarket Decliners
MT
05/31European ADRs Nudge Higher in Tuesday Trading
MT
05/31ERYTECH PHARMA S.A. : Monthly statement on outstanding equity shares and voting rights
CO
More news
News in other languages on ERYTECH PHARMA S.A.
06/28Les ADR européens en baisse dans les échanges de mardi
06/24Compte Rendu – Assemblée Générale Mixte d'ERYTECH du 24 Juin 2022
06/23Les ADR européens sont en baisse jeudi
06/17Les ADR européens sont en baisse vendredi
06/15Les ADR européens sont en hausse mercredi
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 1,12 €
Average target price 3,60 €
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-46.98%37
GILEAD SCIENCES, INC.-13.95%78 031
VERTEX PHARMACEUTICALS27.66%70 632
REGENERON PHARMACEUTICALS, INC.-5.37%64 046
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979